Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

L. Coleman, Robert; F. Fleming, Gini; F. Brady, Mark; M. Swisher, Elizabeth; Dahl Steffensen, Karina; Friedländer, Michael; Okamoto, Aikou; N. Moore, Kathleen; Ben-Baruch, Noa; L. Werner, Theresa; Cloven, Noelle; Oaknin, Ana; DiSilvestro, Paul; A. Morgan, Mark; Nam, Joo‐Hyun; A. Leath, Charles; Nicum, Shibani; R. Hagemann, Andrea; D. Littell, Ramey; Cella, David; Baron‐Hay, Sally; García-Donás, Jesús; Mizuno, Mika; M. Bell‐McGuinn, Katherine; Sullivan, Danielle; Allen Bach, Bruce; Bhattacharya, Sudipta; K. Ratajczak, Christine; Ansell, Peter; H. Dinh, Minh; Aghajanian, Carol; A. Bookman, Michael

doi:10.1056/nejmoa1909707

Public

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Published in New England Journal of Medicine • Sep 28, 2019

Authors:

Robert L. Coleman

Gini F. Fleming

Mark F. Brady

Abstract

BACKGROUND: Data are limited regarding the use of poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance as initial treatment in patients with high-grade serous ovarian carcinoma. METHODS: -mutation cohort), and the...

Subject

Veliparib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!